Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D. Mease PJ, et al. Among authors: woltering f. Ann Rheum Dis. 2014 Jan;73(1):48-55. doi: 10.1136/annrheumdis-2013-203696. Epub 2013 Aug 13. Ann Rheum Dis. 2014. PMID: 23942868 Free PMC article. Clinical Trial.
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, Mease PJ. van der Heijde D, et al. Among authors: woltering f. Ann Rheum Dis. 2014 Jan;73(1):233-7. doi: 10.1136/annrheumdis-2013-203697. Epub 2013 Aug 13. Ann Rheum Dis. 2014. PMID: 23942869 Free PMC article. Clinical Trial.
Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.
Isaacson SH, Boroojerdi B, Waln O, McGraw M, Kreitzman DL, Klos K, Revilla FJ, Heldman D, Phillips M, Terricabras D, Markowitz M, Woltering F, Carson S, Truong D. Isaacson SH, et al. Among authors: woltering f. Parkinsonism Relat Disord. 2019 Jul;64:132-137. doi: 10.1016/j.parkreldis.2019.01.025. Epub 2019 Jan 28. Parkinsonism Relat Disord. 2019. PMID: 30948242 Clinical Trial.
Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
Timmermann L, Asgharnejad M, Boroojerdi B, Dohin E, Woltering F, Elmer LW. Timmermann L, et al. Among authors: woltering f. Expert Opin Pharmacother. 2015;16(10):1423-33. doi: 10.1517/14656566.2015.1049597. Epub 2015 May 22. Expert Opin Pharmacother. 2015. PMID: 25997442 Clinical Trial.
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.
Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, Kiessling P, Woltering F, Griffin L, Van den Bergh P; MG0002 Investigators. Bril V, et al. Among authors: woltering f. Neurology. 2021 Feb 9;96(6):e853-e865. doi: 10.1212/WNL.0000000000011108. Epub 2020 Nov 20. Neurology. 2021. PMID: 33219142 Free PMC article. Clinical Trial.
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
Robak T, Kaźmierczak M, Jarque I, Musteata V, Treliński J, Cooper N, Kiessling P, Massow U, Woltering F, Snipes R, Ke J, Langdon G, Bussel JB, Jolles S. Robak T, et al. Among authors: woltering f. Blood Adv. 2020 Sep 8;4(17):4136-4146. doi: 10.1182/bloodadvances.2020002003. Blood Adv. 2020. PMID: 32886753 Free PMC article. Clinical Trial.
12 results